COPENHAGEN, June 1 /PRNewswire-FirstCall/ -- Genmab A/S (CSE: GEN) announced today that the company will become a member of the Copenhagen Stock Exchange's OMXC20 index as of June 18, 2007. The index is comprised of the 20 most actively traded shares on the Copenhagen Stock Exchange and is revised biannually on the basis of two criteria: turnover in terms of market value and liquidity on the basis of trading frequency. The first trading day of the revised OMXC20 index is June 18, 2007. The old portfolio will be effective up to and including June 15, 2007.
"We are delighted and honored to join some of the largest Danish companies as a member of the prestigious OMXC20 index. This is an important achievement for our industry, as Genmab is the first biotechnology company to enter the index," said Lisa N. Drakeman, Ph.D., Chief Executive Officer at Genmab.
About Genmab A/S
Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody(TM), a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. For more information about Genmab, visit www.genmab.com.
This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome Genmab A/S 2/2 Investor News no. 07/2007 and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law. Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.
Contact: Genmab A/S Toldbodgade 33 1253 Copenhagen K Denmark Tel: +45-7020-2728 Fax: +45-7020-2729 CVR no: 2102-3884 Helle Husted, Sr. Director Investor Relations T: +45-33-44-77-30 M: +45-25-27-47-13 E: hth@genmab.com
Genmab A/SCONTACT: Contact: Genmab A/S Toldbodgade 33, 1253 Copenhagen K, Denmark,Tel: +45-7020-2728, Fax: +45-7020-2729, CVR no: 2102-3884; Helle Husted,Sr. Director, Investor Relations T: +45-33-44-77-30, M: +45-25-27-47-13, E:hth@genmab.com
